文献速递肝病消化道肿瘤与早癌

系统治疗时代下局部区域治疗在肝细胞癌中的作用

Role of locoregional therapies in the wake of systemic therapy.
PubMed 文献 · J Hepatol · 2020-01-01

本文综述肝细胞癌系统治疗新药获批后局部区域治疗(LRT)的角色争议,讨论不可切除HCC何时转向系统治疗及局部联合系统的机会。文中还涉及免疫肿瘤药物与LRT联合的策略、患者选择及临床试验设计挑战。

要点

  • 系统治疗获批试验以晚期HCC为主,也纳入局部治疗后进展者。
  • LRT角色争议聚焦不可切除HCC转向系统治疗的时机。
  • 免疫检查点抑制剂与LRT联合是早期疾病的研究方向。

核心结论

  • 随着多种系统药物获批,LRT在不可切除HCC中的定位需重新审视,重点在于转向系统治疗的时机及局部联合系统的策略。

研究设计与样本

  • 本文为综述,基于近期系统治疗随机对照试验及正在进行的免疫肿瘤药物试验进行讨论。

主要发现

  • 支持系统药物获批的随机对照试验主要在晚期HCC人群中进行,但也纳入部分局部区域治疗后进展的患者,多为经动脉化疗栓塞。

临床怎么用

  • 临床需根据患者选择确定LRT适用人群,并基于科学 rationale 探索局部联合系统治疗。

局限性

  • 本文为综述,未报告具体样本量、效应值或统计学阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple systemic agents have recently been approved in the first- and second-line setting for hepatocellular carcinoma (HCC), increasing the therapeutic options for patients and treating physicians. The randomised controlled trials that led to these approvals were predominantly conducted in a population comprised of patients with advanced HCC. However, these trials also included a subset of patients who had progressed after locoregional therapies (LRTs), mostly transarterial chemoembolisation. With a greater number of systemic agents available, the role of LRTs has become a topic of debate, specifically regarding when to transition to systemic therapy in unresectable HCC and the potential opportunities for combining locoregional and systemic therapies. Trials of immuno-oncology agents (notably T cell checkpoint inhibitors) are ongoing in the advanced disease setting and these agents also present opportunities for combination therapies, both with other systemic agents and with LRTs in earlier stage disease. This article will review strategies to guide patient selection for LRT as well as the development of locoregional-systemic combinations based on scientific rationale and the challenges of clinical trial design in this setting.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Palmer DH, Malagari K, Kulik LM, et al. Role of locoregional therapies in the wake of systemic therapy. J Hepatol. 2020. PMID: 31954492. doi:10.1016/j.jhep.2019.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。